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Pregnant HIV-infected women were screened for the development of HIV-1 drug resistance
after implementation of a triple-antiretroviral transmission prophylaxis as recommended by
the WHO in 2006. The study offered the opportunity to compare amplicon-based 454 ultra-
deep sequencing (UDS) and allele-specific real-time PCR (ASPCR) for the detection of
drug-resistant minor variants in the HIV-1 reverse transcriptase (RT).
Methods
Plasma samples from 34 Tanzanian women were previously analysed by ASPCR for key
resistance mutations in the viral RT selected by AZT, 3TC, and NVP (K70R, K103N,
Y181C, M184V, T215Y/F). In this study, the RT region of the same samples was investi-
gated by amplicon-based UDS for resistance mutations using the 454 GS FLX System.
Results
Drug-resistant HIV-variants were identified in 69% (20/29) of women by UDS and in 45%
(13/29) by ASPCR. The absolute number of resistance mutations identified by UDS was
twice that identified by ASPCR (45 vs 24). By UDS 14 of 24 ASPCR-detected resistance
mutations were identified at the same position. The overall concordance between UDS and
PLOSONE | DOI:10.1371/journal.pone.0140809 October 15, 2015 1 / 16
a11111
OPEN ACCESS
Citation: Hauser A, Kuecherer C, Kunz A, Dabrowski
PW, Radonić A, Nitsche A, et al. (2015) Comparison
of 454 Ultra-Deep Sequencing and Allele-Specific
Real-Time PCR with Regard to the Detection of
Emerging Drug-Resistant Minor HIV-1 Variants after
Antiretroviral Prophylaxis for Vertical Transmission.
PLoS ONE 10(10): e0140809. doi:10.1371/journal.
pone.0140809
Editor: Luis Menéndez-Arias, Centro de Biología
Molecular Severo Ochoa (CSIC-UAM), SPAIN
Received: May 26, 2015
Accepted: September 29, 2015
Published: October 15, 2015
Copyright: © 2015 Hauser et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper.
Funding: This work was supported by the German
Ministry for Economic Cooperation and Development,
project number 01.2029.5 GH and H.W. & J. Hector
Stiftung, Germany GH. The funders had no role in
study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
ASPCR was 61.0% (25/41). The proportions of variants quantified by UDS were approxi-
mately 2–3 times lower than by ASPCR. Amplicon generation from samples with viral loads
below 20,000 copies/ml failed more frequently by UDS compared to ASPCR (limit of detec-
tion = 650 copies/ml), resulting in missing or insufficient sequence coverage.
Conclusions
Both methods can provide useful information about drug-resistant minor HIV-1 variants.
ASPCR has a higher sensitivity than UDS, but is restricted to single resistance mutations.
In contrast, UDS is limited by its requirement for high viral loads to achieve sufficient
sequence coverage, but the sequence information reveals the complete resistance patterns
within the genomic region analysed. Improvements to the UDS limit of detection are in prog-
ress, and UDS could then facilitate monitoring of drug-resistant minor variants in the HIV-1
quasispecies.
Introduction
Antiretroviral regimens for the prevention of mother-to-child transmission (PMTCT) of HIV
have a proven efficacy in resource-limited countries. However, a major drawback of such tem-
porary regimens is the emergence of resistant HIV-1 strains. This was extensively shown for
the nevirapine single-dose (NVP-SD) regimen [1]. The implementation of the 2006 WHO-rec-
ommended triple antiretroviral regimen consisting of antenatal mono-administration of zivo-
duvine (AZT), NVP-SD at labor onset, and AZT plus lamivudine (3TC) for one week
postpartum was assumed to reduce the development of drug resistance [1–3].
Drug resistant variants in HIV-1 protease and reverse transcriptase (RT) are routinely
detected by Sanger population sequencing [4]. However, only mutant variants present at levels
above 20% in the viral quasispecies of the patient can be detected by this method [5, 6], and
more sensitive methods have revealed the frequent presence of drug-resistant variants in the
virus population at frequencies lower than 20%. The sensitive methods were based on real-time
PCR using mutant-specific oligonucleotides (allele-specific real-time PCR, ASPCR) with detec-
tion limits below 1% [7–9].
Using a highly sensitive ASPCR, we recently reported the emergence of drug-resistant
minor HIV-1 variants in the plasma of 40% (20/50) of Tanzanian women following the 2006
WHO recommended PMTCT regimen [10]. In 70% of these women, resistant virus variants
were present as a minority at frequencies below 5% of the total virus population. ASPCR was
performed for the most common and frequent key resistance mutations: K70R selected early
and transiently by AZT and T215Y/F selected by AZT, K103N and Y181C selected by NVP,
and the M184V mutation selected by 3TC. The disadvantage of ASPCR is that a specific PCR-
assay has to be established for each resistance position of interest, which limits the number of
mutations that can be analysed and does not allow the detection of additional resistance-associ-
ated mutations present in the same genome. A more recently developed "ultra-deep sequenc-
ing" (UDS) method is also able to detect and quantify viral minorities [11, 12]. In contrast to
ASPCR, UDS provides information about all mutations that differ from wild type in the geno-
mic region analysed. This method has been used for drug-resistance testing in the HIV-1 prote-
ase [13–17], RT [13–20], and integrase [21] or to predict the HIV-1 co-receptor usage [22, 23]
with sensitivities of less than 1%.
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The aim of the present study was to directly compare the performance of UDS and ASPCR
using a back-up plasma sample of the same sampling date from those pregnant women.
Materials and Methods
Ethics Statement
Ethical approval was obtained from the local Mbeya Medical Research and Ethics Committee,
the National Institute for Medical Research of Tanzania and the ethical committee of Charité –
Universitätsmedizin Berlin in Germany. Informed written consent was obtained from all par-
ticipants involved in the study.
The study cohort
In a previous study, 20/50 women who had taken antenatal AZT, NVP-SD at labor onset and
AZT/3TC for 7 days postpartum were found to carry at least one HIV-1 drug resistance muta-
tion in samples taken at delivery and until 12–16 week postpartum by applying ASPCR. The
study revealed HIV-variants with the AZT-selected mutations in nine (18%) women, NVP-
selected mutations in seven (14%) women, 3TC-selected mutation in one (2%) woman, and
dual- or multi-resistant HIV-populations selected by NVP and 3TC, by AZT and 3TC, or by
AZT, NVP, and 3TC in one woman (2%), respectively. In 7/20 (35%) women, HIV-1 resistance
mutations were also detected by Sanger sequencing [10]. These 20 women with ASPCR-
detected mutations, and 14 additional women in whom ASPCR key resistance mutations were
not identified (34 women in total) were included in this sub-study to compare the previous
ASPCR results with those gained by UDS. HIV RNA was extracted for UDS from 45 postpar-
tum back-up samples (1–4 samples per woman) (Table 1). Viral loads were determined by
TaqMan real-time PCR of the HIV-1 LTR genomic region according to the method published
by Cleland et al. [24]. Back-up samples with a viral load below 1,000 copies/ml (n = 4) were
excluded to minimize stochastic effects of sampling variation [14] and failure of amplicon gen-
eration [25, 26]. Finally, 41 maternal back up samples of 31 mothers (5x delivery, 2x 1–2
weeks, 29x 4–6 week, 5x 12–16 weeks) were analysed by UDS. HIV-1 subtype C was identified
in 68% (21/31) and subtype A1 in 32% (10/31) of the women (Table 1).
Allele-specific real-time PCR
HIV-1 subtype A-, D-, and C-specific ASPCR was established for seven resistance-associated
key mutations selected by AZT (K70R, T215Y/F), 3TC (M184V), and NVP (K103N, Y181C)
with detection limits below 1% as described by Hauser et al. [10, 27].
Amplicon-based UDS
We participated in two international multicentre collaborative studies designed to validate two
versions of an amplicon-based 454 ultra-deep pyrosequencing assay for HIV-1 drug resistance
tested on the GS FLX System [11, 12]. In both studies we also analysed additional samples in a
so-called 'researcher run'. Finally, forty-one postpartum plasma back-up samples from the
study cohort described above were analysed in a researcher run of the follow-up international
multicentre collaborative study [11]. Subtype-generic barcoded primers to amplify protease
and RT and most of the reagents were obtained from 454 Life Sciences/Roche as part of the
study. GS FLX Titanum Chemistry (Roche, Mannheim, Germany) was used, achieving read
lengths of up to 400–500 bases. A 500 μl aliquot of each plasma back-up sample was available,
and viral RNA was extracted according to manufacturer's instructions (Viral RNA-Extraction
Kit, Qiagen, Hilden, Germany). Following the study protocol, 13 μl of RNA (130 μl plasma
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Table 1. Samples included into the sub-study.
Pat No.* Sub type Follow up Sanger Sequence ASPCR Resistance Mutation; % Sample No Viral load (c/ml)
1 C del K70K/R K70R 13 - - - - 1 1.13E+03
2 C del K70K/R K70R 11 - - - - 2 3.26E+03
4w wt wt - - - - - 3 5.24E+04
3 A1 del K70K/R K70R 14 - - - - 4 1.42E+04
4w wt K70R 5.4 - - - - 5 2.21E+04
4 A1 del K70K/R K70R 28 - - - - 6 2.40E+04
4w K70K/R K70R 14 - - - - 7 4.63E+04
5 C del wt K70R 2.0 T215F 0.5 - - 8 3.47E+04
1w K65K/R T215F 0.5 - - - - 9 1.42E+03
4w wt K70R 2.3 - - - - 10 5.44E+04
12w wt T215F 0.7 - - - - 11 8.46E+04
6 A1 4w wt wt - - - - - 12 1.87E+04
7 A1 1w wt K103N 10 - - - - / <1.0E+03
4w wt Y181C 0.8 - - - - / <1.0E+03
8 C 4w wt K103N 1.3 - - - - 13 1.39E+05
9 C 1w wt M184V 0.6 - - - - 14 1.47E+03
4w wt K103N 3.4 - - - - 15 1.65E+04
10 A1 4w wt K70R 4.9 - - - - 16 1.23E+04
11 C 4w wt K70R 2.7 - - - - 17 3.94E+03
12 C 4w wt T215F 0.8 - - - - 18 1.07E+03
13 C 4w wt T215Y 3.9 - - - - 19 3.50E+04
14 A1 4w wt K103N 2.1 - - - - 20 1.23E+03
15 C 4w wt K103N 3.4 - - - - 21 4.69E+03
16 C 4w K103K/N; Y181Y/C; V106V/A M184V 0.6 K103N 36 Y181C 20 22 4.47E+03
13w K103K/N K103N 12 K70R 4.0 - - 23 7.00E+03
17 D 12w wt K103N 0.2 - - - - / <1.0E+03
18 C 12w wt Y181C 0.4 - - - - 24 6.60E+03
19 C 4w wt wt - - - - - 25 9.60E+04
12w G190G/A Y181C 1.5 - - - - 26 6.50E+03
20 C 4w wt wt - - - - - 27 4.67E+05
12w wt M184V 0.6 - - - - 28 2.76E+04
21 A1 4w wt wt - - - - - 29 7.92E+03
22 A1 4w wt wt - - - - - 30 4.87E+04
23 C 4w wts wt - - - - - 31 5.74E+04
24 A1 4w wt wt - - - - - 32 1.63E+05
25 A1 4w wt wt - - - - - 33 4.68E+05
26 C 4w wt wt - - - - - 34 7.00E+03
27 C 4w wt wt - - - - - 35 2.48E+03
28 C 6w wt wt - - - - - 36 1.17E+05
29 A1 4w wt wt - - - - - 37 5.32E+04
30 C 4w wt wt - - - - - 38 1.75E+04
31 C 4w wt wt - - - - - 39 4.63E+03
32 C 4w wt wt - - - - - 40 9.13E+03
33 C 4w wt wt - - - - - 41 7.86E+04
34 A1 4w wt wt - - - - - / <1.0E+03
* according to Hauser et al. [10]
del delivery; w week; c/ml copies per ml; wt wild type sequence (Sanger); wt no ASPCR key resistance mutation detected
doi:10.1371/journal.pone.0140809.t001
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equivalent) were reverse transcribed (Transcriptor Reverse Transcriptase/Protector RNase
Inhibitor/Ribonuclease H, Roche, Mannheim, Germany) using the Roche 4R- and 5R-primers,
resulting in two overlapping cDNA fragments of the HIV protease and RT coding region (nt
2200–3400 of HXB2, Acc. No. K03455). Three microliter of each of the two cDNAs were used
in subsequent PCRs (FastStart High Fidelity PCR System, Roche, Mannheim, Germany) with
primers provided in ready-to-use microtiter plates. Six overlapping amplicons, named RTP1 to
RTP6, were generated by PCR spanning protease codons 10–99 and RT codons 1–251. Ampli-
con sizes including adapters and MID were as follows: RTP1 = 419 bp, RTP2 = 510 bp,
RTP3 = 400 bp, RTP4 = 599 bp, RTP5 = 558 bp and RTP6 = 434 bp [11]. After amplification,
PCR products at concentrations below 5 ng/μl (Quant-iTTM PicoGreen1dsDNA Reagent and
Kit, Invitrogen, Darmstadt, Germany) were further analysed (Agilent 2100 Bioanalyzer, Agi-
lent Technologies, Böblingen, Germany). PCR products with a molar ratio of primer-dimer to
amplicon above 1:3 were excluded from UDS. Subsequently, amplicons RTP1-6 from each
sample were pooled in equimolar proportions. Missing RTPs were compensated with one or
two overlapping amplicons since all regions were covered by more than one amplicon. Clonal
amplification on beads (emulsion PCR), bead isolation (breaking), and sequencing were per-
formed according to manufacturer’s protocol for the GS FLX System (454 Life Sciences/
Roche). Resulting reads were matched to the protease-RT-sequence of HXB2 (Acc. No.
K03455) using the software GS Amplicon Variant Analyzer (version 2.9, 454 Life Sciences/
Roche). To account for the combined error rate of amplicon-based UDS [28–30], a cut-off of
1% [11, 12] represented by at least 10 mutant reads balanced between the forward and reverse
directions [16, 25] was applied to define valid unknown drug resistant minor HIV-1 variants.
To compare directly UDS and ASPCR for six known key resistance mutations analysed by
ASPCR (K70R, K103N, Y181C, M184V, T215Y/F), we also permitted a cut-off of less than 1%
if at least 10 mutant reads balanced between the forward and reverse directions were present.
The suitability of these settings was confirmed by analysing the sensitivity of detection of
seven resistance mutations in the RT as well as the error rate for all drug resistance mutations
according to the IAS 2014 list [31]. This was done using recombinant HIV-1 from the wild-
type pNL4.3 clone (Acc. No. M19921) and a mutant pNL4.3 derived clone that harbours seven
resistance mutations in the RT (M41L, A62V, A98G, K103N, V118I, L210W, T215Y). Cloning
and generation of the recombinant virus has been described previously [10, 32]. By analysing
five samples of recombinant wild-type virus NL4.3 with viral loads ranging from 103 to 109
copies/ml, we found the highest error rate for unknown drug resistance mutations detected in
our sample panel to be 0.25% for E138K. The error rate of the six key resistance mutations ana-
lysed by ASPCR was 0% each. Each of the seven RTI mutations were detected at levels above
their natural specific error rates in mixtures of the wild-type recombinant HIV-1 containing
0.5% to 50% of the mutant (viral load 109 copies/ml). The lowest proportion quantified was
0.32% T215Y in the 0.5% mixture.
For statistical analysis two sided Fisher’s exact test was applied and p-values<0.05 were
considered to be significant.
Results
Amplicon-based UDS
Amedian viral load of 17,533 copies/ml (IQR 4,687–53,158) was determined for the 41 mater-
nal back up samples of 31 women. PCR resulted in two to six amplicons (RTPs) per sample for
38/41 samples, while amplification failed totally for three samples (samples No. 14, 24, 26;
Table 2) with low viral loads (1,470/6,600/6,500 copies/ml, respectively). Thus, 38 samples of
30 women were further analysed (Table 2).
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Table 2. Outcome of UDS amplicon generation and sequencing regarding detection of drug-resistant (AZT, 3TC, NVP) HIV-1 variants.
Pat No. * Sample No. Viral load (c/ml) RTP (n) RT region (aa pos) ASPCR
Resistance
Mutation; %
Total reads Mutant reads
1 1 1.13E+03 3 1–251 wt - - -
2 2 3.26E+03 2 1–251 K70R 10 13228 1318
E138A 97.6 13252 12937
3 5.24E+04 5 1–237 Y181C 1.2 6379 78
3 4 1.42E+04 5 1–251 K70R 6.5 8267 536
V108I 7.5 3964 299
5 2.21E+04 5 1–251 K70R 2.0 3104 63
V108I 2.0 1076 22
4 6 2.40E+04 5 1–251 K70R 9.6 7896 754
E138K 3.6 3691 134
7 4.63E+04 5 1–251 K70R 9.0 6960 626
T215I 9.1 4580 416
5 8 3.47E+04 6 1–251 wt - - -
9 1.42E+03 2 145–251 wt - - -
10 5.44E+04 5 1–251 K65R 1.7 1665 28
11 8.46E+04 3 1–251 wt - - -
6 12 1.87E+04 3 1–251 wt - - -
8 13 1.39E+05 6 1–251 K65R 1.1 1905 20
K101E 6.3 1787 113
K103N 7.1 1787 127
9 14 1.47E+03 0 n.a. n.a. - - -
15 1.65E+04 4 1–251 K101E 3.6 1203 43
K103R 1.2 1202 14
V106M 3.7 1202 45
G190A 1.5 3769 57
P225H 1.1 3772 40
10 16 1.23E+04 3 1–251 K70R 5.4 1507 81
V108I 3.9 1506 58
11 17 3.94E+03 6 1–251 K70R 1.0 1935 20
12 18 1.07E+03 3 1–237 V90I 4.4 1610 71
13 19 3.50E+04 4 1–237 wt - - -
14 20 1.23E+03 3 1–170 wt - - -
15 21 4.69E+03 3 1–170 V106I 2.0 1715 34
16 22 4.47E+03 5 1–251 K103N 41.9 845 354
V106A 10.3 845 87
Y181C 11.4 3151 358
G190A 1.6 3150 49
23 7.00E+03 2 1–251 K103N 3.6 3525 126
18 24 6.60E+03 0 n.a. n.a. - - -
19 25 9.60E+04 6 1–251 K65R 1.0 7478 74
M184I 1.3 9141 117
G190A 99.1 9141 9060
26 6.50E+03 0 n.a. n.a. - - -
20 27 4.67E+05 6 1–251 K65R 1.0 9733 95
28 2.76E+04 4 1–80,145–251 M184I 6.1 9556 582
(Continued)
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A total of 154/228 (68%) PCR amplicons was generated (median 4 RTPs/sample, IQR 3–5).
Amplification of RTP4 (10/38) was significantly less successful compared to RTP1 (30/38),
RTP2 (27/38), RTP3 (31/38), RTP5 (30/38), and RTP6 (26/38) (RTP4 vs RTP1-3/5-6: all
p<0.001). Successful generation of amplicons significantly correlated with viral loads above
20,000 copies/ml (66/114 vs 88/114: p = 0.003). Amplification success did not depend on the
HIV-1 subtype, because 107/156 RTPs were amplified from subtype C-isolates and 47/72 from
subtype A1-isolates (p = 0.650) (Table 2).
The failure of RTP generation could be compensated in 20/33 samples by overlapping RTPs
(data not shown). Analysis of the entire RT-genomic region (amino acids (aa) 1–251 of RT)
was therefore possible for 25/38 samples. However, in 13 samples the RT-region was not fully
covered: the 3'-RT-region downstream of the aa position 170 or 237 was missing in ten samples
(no compensation for RTP4 and RTP6 or for RTP6 only, respectively) and the 5'-RT-region
upstream of the aa position 145 was missing in three samples (no compensation of RTP1-4 or
RTP 4–5, respectively).
A median number of 16,735 reads per sample was obtained (IQR 13,024–23,043), and drug
resistance mutations were detected with coverages ranging from 845 to 13,252. In total, 45
drug-selected resistant variants were identified by amplicon-based UDS in 25 samples. Nine
resistant variants with the AZT-selected mutations K70R and/or T215I were identified in eight
samples at frequencies of 1.0% to 10.0%. Twenty-eight NVP-selected mutations (V90I, K101E,
K103N/R, V106A/I/M, V108I, E138A/G/K/R, Y181C, Y188C, G190A or P225H) were detected
in 19 samples at levels of 1.1% to 99.1%. Seven 3TC-selected mutations (K65R or M184I) were
present in six samples at frequencies of 1.0% to 6.1% (Table 2). From a total of 45 resistance
mutations, 18 (40%) were present at ASPCR key resistance positions, while 27 (60%) were
Table 2. (Continued)
Pat No. * Sample No. Viral load (c/ml) RTP (n) RT region (aa pos) ASPCR
Resistance
Mutation; %
Total reads Mutant reads
21 29 7.92E+03 4 1–237 E138K 2.2 6006 131
22 30 4.87E+04 3 1–251 wt - - -
23 31 5.74E+04 5 1–251 V108I 1.6 6939 111
24 32 1.63E+05 4 1–170 E138A 29.1 4840 1408
E138G 3.9 4840 188
E138R 3.9 4840 188
25 33 4.68E+05 5 1–251 wt - - -
26 34 7.00E+03 2 145–251 Y188C 5.1 10500 534
27 35 2.48E+03 4 1–251 wt - - -
28 36 1.17E+05 4 1–170 wt - - -
29 37 5.32E+04 2 1–170 wt - - -
30 38 1.75E+04 3 1–251 K65R 1.1 4331 46
31 39 4.63E+03 4 1–170 wt - - -
32 40 9.13E+03 5 1–251 Y181C 2.0 6750 133
33 41 7.86E+04 5 1–251 K70R 1.0 6545 62
K101E 6.9 3997 276
* according to Hauser et al. [10]
aa amino acid; c/ml copies per ml; coverage: min and max number of reads per position; UDS RTP (n) number of successfully generated overlapping
amplicons out of six; n.a. not analyzed; wt wild type sequence
doi:10.1371/journal.pone.0140809.t002
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detected at nine additional positions in RT not analysed by ASPCR. No drug-resistant variants
were detected in 13 samples, but for nine of these samples presence of drug-resistant variants
cannot be excluded due to missing regions in the RT (Table 2).
Comparison of UDS with ASPCR and Sanger sequencing
For comparison of UDS and ASPCR, only key resistance mutations localized at RT positions
K70, K103, Y181, M184, and T215 were considered. For comparison of UDS and Sanger
sequencing, the positions V106 and K65 were also investigated.
Twenty-four HIV-1 resistance mutations were detected in 20 samples by ASPCR: 16x
selected by AZT (11x K70R, 4x T215F, 1x T215Y), 6x selected by NVP (5x K103N, 1x Y191C),
2x selected by 3TC (2x M184V), while in 17 samples no key resistance mutations were detected
(Tables 1 and 3).
The presence of 12/24 (50%) ASPCR-detected resistance mutations could be reproduced by
UDS. For eight of these, mutant variants were quantified at a lower proportion by UDS com-
pared to ASPCR (median: 2.7 times lower; IQR 2.1–3.0). In one sample, the proportion of
mutant variant was 5.5 times higher by UDS than by ASPCR (sample No. 13: 7.1% vs 1.3%). In
three samples the proportions quantified by UDS and ASPCR were very similar, showing maxi-
mally 10% difference (0.1–1.1 times; sample No. 2: 10.0% vs 11%, sample No. 16: 5.4% vs 4.9%;
sample No. 22: 41.9% vs 36%) (Table 3).
In 13/24 (54%) samples, the ASPCR-detected key resistance mutations could not be con-
firmed by UDS. All mutations but one were present at low (<5%; n = 5) or at very low (<1%;
n = 6) frequencies. Notably, in two of these samples other resistance mutations were detected
at the same position in the RT with a different aa substitution than that revealed by ASPCR
(sample No. 15: K103R instead of K103N; sample No. 28: M184I instead of M184V) (Table 3).
For 13/17 samples, the absence of key resistance mutations as analysed by ASPCR was con-
firmed by UDS (inclusive sample No. 25 with M184I). However, in four cases very low propor-
tions of key resistance mutations were detected by UDS: 0.5% K70R (sample No. 33) 1.0%
K70R (sample No. 41), 1.2% Y181C (sample No. 3), and 2.0% (sample No. 40). The propor-
tions of K70R quantified by UDS were close to the ASPCR detection limit (0.99% for K70R),
whereas the proportions of Y181C quantified by UDS were above the ASPCR detection limit
(0.35% for Y181C) [10] (Table 3).
All eight key resistance mutations detected by Sanger sequencing were confirmed by
ASPCR, whereas UDS missed one mutation (sample No. 1: K70K/R). With two exceptions
(both in sample No. 22), the proportions of drug-resistant variants were>11% by ASPCR and
11% by UDS. Of two additional mutations (sample No. 9: K65K/R, sample No. 22: V106V/
A) detected by Sanger sequencing, V106A was identified by UDS at<11%, whereas the K65R
could not be confirmed due to insufficient RTP coverage (Tables 2 and 3).
Prediction of drug-resistance based on UDS and ASPCR results
Fourty-five drug resistance mutations were detected by UDS in 25 back-up samples of 20
women compared to 24 drug resistance mutations detected by ASPCR in 20 samples of 13
women (Table 4).
Based on the UDS results, 69% (20/29) of women harboured drug-resistant HIV variants
(cumulative resistance of all follow up samples, Table 4): AZT-resistance mutations were iden-
tified in six, NVP-resistance in 16 and 3TC-resistance in five women, resulting in mono-resis-
tance to AZT in 3% (1/29), NVP in 31% (9/29), and 3TC in 10% (3/29) of the women. Dual-
resistant virus populations were present in 24% (7/29), either selected by AZT and NVP
Minor Resistance Detected by UDS and Allele-Specific PCR
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Table 3. Comparison of UDS, ASPCR, and Sanger sequencing.





Total reads Mutant reads
Mutations detected by UDS and ASPCR (and/or Sanger)
2 3.26E+03 K70K/R K70R 11 K70R 10.0 13228 1318
4 1.42E+04 K70K/R K70R 14 K70R 6.5 8267 536
5 2.21E+04 wt K70R 5.4 K70R 2.0 3104 63
6 2.40E+04 K70K/R K70R 28 K70R 9.6 7896 754
7 4.63E+04 K70K/R K70R 14 K70R 9.0 6960 626
8 3.47E+04 wt K70R 2.0 K70R 0.3 7882 27
13 1.39E+05 wt K103N 1.3 K103N 7.1 1787 127
16 1.23E+04 wt K70R 4.9 K70R 5.4 1507 81
17 3.94E+03 wt K70R 2.7 K70R 1.0 1935 20
22 4.47E+03 K103K/N K103N 36 K103N 41.9 845 354
Y181Y/C Y181C 20 Y181C 11.4 3151 358
23 7.00E+03 K103K/N K103N 12 K103N 3.6 3525 126
12 1.87E+04 wt wt - wt - - -
27 4.67E+05 wt wt - wt - - -
29 7.92E+03 wt wt - wt - - -
30 4.87E+04 wt wt - wt - - -
31 5.74E+04 wt wt - wt - - -
32 1.63E+05 wt wt - wt - - -
34 7.00E+03 wt wt - wt - - -
35 2.48E+03 wt wt - wt - - -
36 1.17E+05 wt wt - wt - - -
37 5.32E+04 wt wt - wt - - -
38 1.75E+04 wt wt - wt - - -
39 4.63E+03 wt wt - wt - - -
Mutations detected by ASPCR (and/or Sanger) but not by UDS
1 1.13E+03 K70K/R K70R 13 K70R - 3363 <10
8 3.47E+04 wt T215F 0.5 T215F - 4142 0
9 1.42E+03 wt T215F 0.5 T215F - 11661 0
K65K/R n.a. - K65R - 0 0
10 5.44E+04 wt K70R 2.3 K70R - 1665 0
11 8.46E+04 wt T215F 0.7 T215F - 11661 0
15 1.65E+04 wt K103N 3.4 K103N - 1202 0
18 1.07E+03 wt T215F 0.8 T215F - 1606 0
19 3.50E+04 wt T215Y 3.9 T215Y - 1487 0
20 3.40E+04 wt K103N 2.1 K103N - 144 0
21 4.69E+03 wt K103N 3.4 K103N - 1715 0
22 4.47E+03 wt M184V 0.6 M184V - 3151 0
23 7.00E+03 wt K70R 4.0 K70R - 5521 <10
28 2.76E+04 wt M184V 0.6 M184V - 9556 <10
Mutations detected by UDS but not by ASPCR (and/or Sanger)
3 5.24E+04 wt wt - Y181C 1.2 6379 78
7 4.63E+04 wt n.a. - T215I 9.1 4580 416
15 1.65E+04 wt n.a. - K103R 1.2 1202 14
22 4.47E+03 V106V/A n.a. - V106A 10.3 845 87
(Continued)
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(n = 5) or by NVP and 3TC (n = 2). No multi-resistance (AZT/NVP/3TC) was detected by
UDS. Wild-type virus was present in 9/29 women (31%) (Table 4).
Based on the ASPCR results, drug-resistance was found to affect 45% (13/29) of women.
AZT-resistance mutations were detected in ten, NVP-resistance in four, and 3TC-resistance in
two women. These mutations resulted in mono-resistance to AZT in 31% (9/29), NVP in 10%
(3/29), and 3TC in 3% (1/29) of women. Multi-resistant virus (AZT/NVP/3TC) was detected
in one woman. No key resistance mutation was detected by ASPCR in 52% (15/29) of women
(Table 4).
Resistant HIV-1 variants in proportions below 5% of the total viral population were present
in 45% (9/29) and in 57% (8/14) of women according to the quantification by UDS and
ASPCR, respectively (Tables 1 and 2).
Discussion
Forty-one samples of 31 Tanzanian women pre-screened in a previous study [10] by ASPCR
for HIV-1 genomes carrying key resistance mutations selected by AZT, 3TC, and NVP were
investigated by UDS to compare the presence of drug-resistance mutations and to identify
additional antiretroviral regimen-selected resistance mutations in the HIV-1 RT-region. The
amplicon-based UDS and the ASPCR were performed using independently isolated RNA of
two different aliquots of the same plasma sample. The results obtained using the two methods
were compared.
In the amplicon-based UDS, 45 AZT-, 3TC-, and/or NVP-selected resistance mutations
were detected in 25 of 37 back-up samples collected from 29 mothers at and after delivery.
Only half of the ASPCR-detected resistance mutations identified previously [10] could be
reproduced by UDS using back-up samples. The potential reasons for this discrepancy are dis-
cussed below.
The generation of amplicons is an essential and critical step in the UDS-workflow. Applying
the HIV-1 primers designed for 454 FLX sequencing by Roche, only two-thirds of the potential
amplicons were amplified successfully. The significantly lower RTP4 primer-efficiency in PCR
is probably the consequence of the larger fragment size as compared to the other amplicons.
Statistical analysis revealed a highly significant correlation between viral load and amplicon
generation of RTP1-6, which was also shown for other UDS assays [25, 26]. Samples with viral
loads above 20,000 copies/ml were amplified more efficiently than samples with viral loads
below or equal to 20,000 copies/ml. In fact, all three samples failing RTP amplification had low
viral loads (<7,000 copies/ml). Likewise, five samples with incomplete RT coverage (RT codon
1–170, 1–236, or 145–251 instead of codon 1–251) had very low viral loads (<5,000 copies/ml),
Table 3. (Continued)





Total reads Mutant reads
25 9.60E+04 wt n.a. - M184I 1.3 9141 117
28 2.76E+04 wt n.a. - M184I 6.1 9556 582
33 4.68E+05 wt wt - K70R 0.5 10756 52
40 9.13E+03 wt wt - Y181C 2.0 6750 133
41 7.86E+04 wt wt - K70R 1.0 6545 62
c/ml copies per ml; n.a. not analysed; wt wild type sequence (Sanger); wt no key resistance mutation detected
doi:10.1371/journal.pone.0140809.t003
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and therefore no sequence was obtained in the respective 3'-region or 5'-region of RT. The
primer design can be considered as generic for HIV-1 subtypes A and C, because both subtypes
were amplified with the same success rate. The impact of the larger RTP4 fragment size as well
as the correlation between viral load and amplicon generation has also been discussed by











1 1 - - - - - K70R - - s AZT
2 2 K70R E138A - - - K70R - - AZT/NVP AZT
3 Y181C - - - - - - -
3 4 K70R V108I - - - K70R - - AZT/NVP AZT
5 K70R V108I - - - K70R - -
4 6 K70R E138K - - - K70R - - AZT/NVP AZT
7 K70R T215I - - - K70R - -
5 8 - - - - - K70R T215F - 3TC AZT
9 - - - - - T215F - -
10 K65R - - - - K70R - -
11 - - - - - T215F - -
6 12 - - - - - - - - s s
8 13 K65R K103N K101E - - K103N - - 3TC/NVP NVP
9 15 K101E K103R V106M G190A P225H K103N - - NVP NVP
10 16 K70R V108I - - - K70R - - AZT/NVP AZT
11 17 K70R - - - - K70R - - AZT AZT
12 18 V90I - - - - T215F - - NVP AZT
13 19 - - - - - T215Y - - s AZT
15 21 V106I - - - - K103N - - NVP NVP
16 22 K103N V106A Y181C G190A - M184V K103N Y181C NVP AZT/NVP/3TC
23 K103N - - - - K103N K70R -
19 25 M184I K65R G190A - - - - - 3TC/NVP s
20 27 K65R - - - - - - - 3TC 3TC
28 M184I - - - - M184V - -
21 29 E138K - - - - - - - NVP s
22 30 - - - - - - - - s s
23 31 V108I - - - - - - - NVP s
24 32 E138A/G/
R
- - - - - - - NVP s
25 33 - - - - - - - - s s
26 34 Y188C - - - - - - - NVP s
27 35 - - - - - - - - s s
28 36 - - - - - - - - s s
29 37 - - - - - - - - s s
30 38 K65R - - - - - - - 3TC s
31 39 - - - - - - - - s s
32 40 Y181C - - - - - - - NVP s
33 41 K70R K101E - - - - - - AZT/NVP s
* according to Hauser et al. [10]
s susceptible; Cum Res/Pat Cumulative resistance per patient
doi:10.1371/journal.pone.0140809.t004
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St. John et al. [11] in line with the follow-up international multicentre collaborative study.
According to our data, a minimum input of 20,000 copies/ml and an extraction volume of
500 μl plasma should be considered for UDS to guarantee successful amplification of all six
amplicons, confirming the 454 recommendation of using the equivalent of at least 2,000 copies
per 10 μl RNA [11, 12].
The sensitivity of UDS depends on the mutation-specific error rate, the read coverage at the
drug resistance position, and the input viral load of the sample [14, 15, 17–19, 33]. A coverage
of at least 50 mutant reads in a total of 5000 reads at the position of interest is recommended to
reliably detect minorities at 1% [34]. However, in our hands the UDS coverage was below 5000
reads for 29/45 drug resistance mutations. Because the site-specific error rate at all detected
drug resistance mutations was below 0.25% in control samples, we permitted a frequency of
1% (represented by a minimum number of 10 mutant reads in a total of 1000 reads) to identify
unknown drug-resistant minor variants [16, 25]. Nevertheless, it should be stressed that these
settings were used for research only in this study, and that this procedure might be inappropri-
ate for resistance testing and decisions concerning therapy.
Only 12/24 drug resistance mutations detected by ASPCR were confirmed by UDS at pre-
dominantly lower frequencies. Indeed, proportions quantified by UDS were on average three
times lower than those quantified by ASPCR. Similarly, all resistance mutations identified by
Sanger sequencing [10] were quantified by UDS with proportions of11% but>11% by
ASPCR, although the detection limit of Sanger sequencing is well known to be approximately
20% [5, 6]. Therefore, UDS seems to underestimate the true proportion of mutant variants,
which might be a reason for the failure of UDS in reproducing minor variants with frequencies
below 5% or even 1% as determined by ASPCR. Another study from Delobel et al. [35], who
compared the performance of 454 UDS and ASPCR to detect the K103N resistance mutation,
also found ASPCR to be more sensitive. The overall concordance of UDS and ASPCR was
therefore 61.0% (25/41) for the absence (n = 13/17) and presence (n = 12/24) of resistance
mutations.
Discrepant results between the samples used in the previous ASPCR analysis and the back-
up samples used in the current UDS analysis can be explained by the fact that the proportion
of the resistant variant was near the detection limit. At concentrations close to the detection
limit, the amplification of independent aliquots drawn from the same sample will lead to
inconsistent results according to the Poisson distribution [14]. Furthermore, more than a half
(7/13) of the samples containing minor drug-resistant HIV-1 variants according to ASPCR not
detected by UDS had viral loads below 20.000 copies/ml and for 5/7 samples only 2–3 RTP
amplicons could be generated. In the ASPCR a shorter PCR fragment (644 bp) was amplified,
resulting in a more sensitive detection limit of 650 copies/ml [10] as compared to UDS. In
addition, in two strains with key resistance mutations detected by ASPCR, a mutation with a
different amino acid substitution at the same position was identified by UDS. This presumes
that a mutant-specific ASPCR primer, which was designed to distinguish between a specific
mutation and the wild type, could misprime at the same position and give positive signals for
any “not wild-type” nucleotide. This may result in a qualitatively correct result (mutant) but
the type and quantity of mutant would not be valid. Indeed, ASPCR may be prone to errors as
a result of polymorphisms in the primer binding sites that limit the success of the assay [10,
27]. Considering this non-wild-type amino acid substitutions as concordant between UDS and
ASPCR, the overall concordance of UDS and ASPCR would increase to 65.9% (25/41) for the
absence (n = 13/17) and presence (n = 12/24) of resistance mutations.
In the present study, the total number of resistance mutations detected by UDS was almost
twice that of the number detected by ASPCR (45 vs 24). However, 60% of these mutations were
present at nine additional positions in the RT which were not covered by the ASPCR assays
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applied here. The presence of NVP- and 3TC-selected resistance mutations was therefore
underestimated by ASPCR as compared to UDS (NVP: 4 vs 15, 3TC: 2 vs 5). Consequently,
UDS revealed dual-resistant HIV-populations in 45% of women compared to 6% of women
with dual/multi-resistant HIV-populations identified by ASPCR. Furthermore, the more sensi-
tive detection limit of the ASPCR (<1%) compared to UDS (1%) resulted in higher propor-
tions of minor variants<5% detected by ASPCR than by UDS (57% vs 45%). Resistance
mutations present in low frequencies such as the AZT resistance mutations, in particular the
minor mutation T215Y/F that occurred at low proportions of<1% due to the higher genetic
barrier of two amino acid substitutions, were therefore underestimated by UDS as compared to
ASPCR (6 vs 10). The clinical relevance of drug-resistant minor variants is still a matter of
debate and their impact on treatment outcome may depend on the type of drug resistance
mutation and the viral load [8, 9, 33–35]. Nevertheless, a recently published Europe-wide case-
control study using 454 UDS demonstrated that drug-resistant minor variants more than dou-
ble the risk of virological failure for first-line therapy including NNRTI [36], which highlights
the need for more sensitive drug-resistance testing methods also in clinical routine.
Conclusions
Despite the small number of patient samples analysed in this comparative study, some conclu-
sions can be drawn about the general benefits or limitations of the two methods.
In the present work, by UDS almost twice the number of mutations as compared to the
ASPCR were detected at nine additional positions. This fact reveals the limitation of ASPCR in
its restriction to only one mutation that can be targeted per reaction. Analysing an amplicon by
UDS provides detailed information of all resistance mutations present in the complete genome
fragment sequenced and thus provides more comprehensive predictions of drug-resistance for
subsequent antiretroviral treatments.
In contrast, the UDS outcome presented here was strongly limited by the less sensitive PCR
and the lower detection limit for resistance mutations. A minimum input of 20,000 copies/ml
is a prerequisite for successful amplification and for sufficient sequence coverage and, in turn, a
reliable cut-off to detect mutant variants at 1% proportions.
Both methods render the detection of drug-resistant virus populations more sensitive than
Sanger sequencing and can allow their detection at frequencies as low as 1%. Despite the fact
that the clinical relevance of these minor variants for treatment response is not yet established,
sensitive detection methods are essential for assessing the prevalence of drug-resistant minor
variants and their impact on treatment outcome. Methodological advances in UDS-technology
will definitively offer the ability to routinely monitor the presence of minor variants in the HIV
quasispecies.
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